{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T21:44:12Z","timestamp":1792532652081,"version":"4.5.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T00:00:00Z","timestamp":1728950400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","annalsofvascularsurgery.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Vascular Surgery"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.avsg.2024.10.003","type":"journal-article","created":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T02:01:51Z","timestamp":1729130511000},"page":"460-468","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"PB","title":["Ability of Activated Clotting Time Measurements to Monitor Unfractionated Heparin Activity During NonCardiac Arterial Procedures"],"prefix":"10.1016","volume":"110","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5059-0107","authenticated-orcid":false,"given":"Max","family":"Hoebink","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A.H.","family":"Steunenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liliane C.","family":"Roosendaal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arno M.","family":"Wiersema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrike M.","family":"Hamer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kak Khee","family":"Yeung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Jongkind","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.avsg.2024.10.003_bib1","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1051\/ject\/202052212","article-title":"Can we rely on the activated clotting time to measure heparin anticoagulation? A clinical evaluation of two ACT monitors","volume":"52","author":"Nilsson","year":"2020","journal-title":"J Extra Corpor Technol"},{"key":"10.1016\/j.avsg.2024.10.003_bib2","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1177\/0267659120949351","article-title":"A comparative analysis of four activated clotting time measurement devices in cardiac surgery with cardiopulmonary bypass","volume":"36","author":"Li","year":"2021","journal-title":"Perfusion"},{"key":"10.1016\/j.avsg.2024.10.003_bib3","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1093\/labmed\/lmz014","article-title":"Intraoperative monitoring of heparin: comparison of activated coagulation time and whole blood heparin measurements by different point-of-care devices with heparin concentration by laboratory-performed plasma anti-xa assay","volume":"50","author":"Thompson","year":"2019","journal-title":"Lab Med"},{"key":"10.1016\/j.avsg.2024.10.003_bib4","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S0022-5223(05)80008-X","article-title":"The impact of heparin concentration and activated clotting time monitoring on blood conservation. A prospective, randomized evaluation in patients undergoing cardiac operation","volume":"110","author":"Despotis","year":"1995","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.avsg.2024.10.003_bib5","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1055\/s-0038-1650684","article-title":"More effective suppression of hemostatic system activation in patients undergoing cardiac surgery by heparin dosing based on heparin blood concentrations rather than ACT","volume":"76","author":"Despotis","year":"1996","journal-title":"Thromb Haemostasis"},{"key":"10.1016\/j.avsg.2024.10.003_bib6","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.avsg.2021.04.023","article-title":"More effective anticoagulation during non-cardiac arterial procedures using activated clotting time guided heparin administration","volume":"76","author":"Doganer","year":"2021","journal-title":"Ann Vasc Surg"},{"key":"10.1016\/j.avsg.2024.10.003_bib7","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.jvs.2017.11.079","article-title":"Comparison between activated clotting time and anti-activated factor X activity for the monitoring of unfractionated heparin therapy in patients with aortic aneurysm undergoing an endovascular procedure","volume":"68","author":"Dieplinger","year":"2018","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.avsg.2024.10.003_bib8","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1093\/bja\/ael194","article-title":"Anticoagulation monitoring during vascular surgery: accuracy of the Hemochron low range activated clotting time (ACT-LR)","volume":"97","author":"Tremey","year":"2006","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.avsg.2024.10.003_bib9","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.3390\/diagnostics13081489","article-title":"Laboratory assessment of unfractionated heparin (UFH) with activated clotting time (ACT) and anti-xa activity during peripheral arterial angiographic procedure","volume":"13","author":"Helin","year":"2023","journal-title":"Diagnostics"},{"key":"10.1016\/j.avsg.2024.10.003_bib10","doi-asserted-by":"crossref","first-page":"3054","DOI":"10.1161\/CIRCULATIONAHA.112.120030","article-title":"Stroke after carotid stenting and endarterectomy in the carotid revascularization endarterectomy versus stenting trial (CREST)","volume":"126","author":"Hill","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.avsg.2024.10.003_bib11","doi-asserted-by":"crossref","DOI":"10.1093\/bjsopen\/zrab086","article-title":"Short-term outcomes of open surgical abdominal aortic aneurysm repair from the Dutch Surgical Aneurysm Audit","volume":"5","author":"Geraedts","year":"2021","journal-title":"BJS Open"},{"issue":"3 Suppl","key":"10.1016\/j.avsg.2024.10.003_bib12","doi-asserted-by":"crossref","first-page":"188s","DOI":"10.1378\/chest.126.3_suppl.188S","article-title":"Heparin and low-molecular-weight heparin: the seventh ACCP conference on antithrombotic and thrombolytic therapy","volume":"126","author":"Hirsh","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.avsg.2024.10.003_bib13","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.jtcvs.2012.05.065","article-title":"Subtle differences in commercial heparins can have serious consequences for cardiopulmonary bypass patients: a randomized controlled trial","volume":"144","author":"Arsenault","year":"2012","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.avsg.2024.10.003_bib14","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.ejvs.2022.08.005","article-title":"Editor's choice - sex differences in response to administration of heparin during non-cardiac arterial procedures","volume":"64","author":"Roosendaal","year":"2022","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1016\/j.avsg.2024.10.003_bib15","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1161\/01.CIR.103.7.961","article-title":"Defining the optimal activated clotting time during percutaneous coronary intervention aggregate results from 6 randomized, controlled trials","volume":"103","author":"Chew","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.avsg.2024.10.003_bib16","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/j.1875-9114.2011.01049.x","article-title":"Antifactor Xa levels versus activated partial thromboplastin time for monitoring unfractionated heparin","volume":"32","author":"Vandiver","year":"2012","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.avsg.2024.10.003_bib17","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ejvs.2019.08.007","article-title":"No concluding evidence on optimal activated clotting time for non-cardiac arterial procedures","volume":"59","author":"Doganer","year":"2020","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1016\/j.avsg.2024.10.003_bib18","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1051\/ject\/201244015","article-title":"Comparison of point-of-care activated clotting time systems utilized in a single pediatric institution","volume":"44","author":"Ojito","year":"2012","journal-title":"J Extra Corpor Technol"},{"key":"10.1016\/j.avsg.2024.10.003_bib19","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1213\/ANE.0b013e31827e4e62","article-title":"Review article: heparin sensitivity and resistance: management during cardiopulmonary bypass","volume":"116","author":"Finley","year":"2013","journal-title":"Anesth Analg"},{"key":"10.1016\/j.avsg.2024.10.003_bib20","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.avsg.2020.07.035","article-title":"A standardized bolus of 5 000 IU of heparin does not lead to adequate heparinization during non-cardiac arterial procedures","volume":"71","author":"Doganer","year":"2021","journal-title":"Ann Vasc Surg"},{"key":"10.1016\/j.avsg.2024.10.003_bib21","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.avsg.2022.01.029","article-title":"Weight based heparin dosage with activated clotting time monitoring leads to adequate and safe anticoagulation in non-cardiac arterial procedures","volume":"84","author":"Doganer","year":"2022","journal-title":"Ann Vasc Surg"},{"key":"10.1016\/j.avsg.2024.10.003_bib22","doi-asserted-by":"crossref","first-page":"825","DOI":"10.7326\/0003-4819-158-11-201306040-00007","article-title":"Kidney Disease: improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline","volume":"158","author":"Stevens","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.avsg.2024.10.003_bib24","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1053\/j.jvca.2015.09.019","article-title":"Validation of a new classification method of postoperative complications in patients undergoing coronary artery surgery","volume":"30","author":"Kinnunen","year":"2016","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"10.1016\/j.avsg.2024.10.003_bib25","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1213\/ANE.0000000000002864","article-title":"Correlation coefficients: appropriate use and interpretation","volume":"126","author":"Schober","year":"2018","journal-title":"Anesth Analg"},{"key":"10.1016\/j.avsg.2024.10.003_bib26","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1053\/j.jvca.2012.03.011","article-title":"An evaluation of factors affecting activated coagulation time","volume":"26","author":"Bosch","year":"2012","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"10.1016\/j.avsg.2024.10.003_bib27","doi-asserted-by":"crossref","first-page":"417","DOI":"10.3949\/ccjm.86a.18029","article-title":"Anti-Xa assays: what is their role today in antithrombotic therapy?","volume":"86","author":"Hutt Centeno","year":"2019","journal-title":"Cleve Clin J Med"},{"key":"10.1016\/j.avsg.2024.10.003_bib28","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1177\/1076029616660761","article-title":"Factors influencing ACT after intravenous bolus administration of 100 IU\/kg of unfractionated heparin during cardiac catheterization in children","volume":"23","author":"Muster","year":"2017","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.avsg.2024.10.003_bib29","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/clpt.1981.53","article-title":"Heparin kinetics: variables related to disposition and dosage","volume":"29","author":"Cipolle","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.avsg.2024.10.003_bib30","first-page":"782","article-title":"College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: laboratory monitoring of unfractionated heparin therapy","volume":"122","author":"Olson","year":"1998","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.avsg.2024.10.003_bib31","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1093\/bja\/aet384","article-title":"Limits of agreement between measures obtained from standard laboratory and the point-of-care device Hemochron Signature Elite(R) during acute haemorrhage","volume":"112","author":"Gauss","year":"2014","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.avsg.2024.10.003_bib32","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.pathol.2019.05.002","article-title":"The accuracy of a point of care measurement of activated partial thromboplastin time in intensive care patients","volume":"51","author":"Karigowda","year":"2019","journal-title":"Pathology"},{"key":"10.1016\/j.avsg.2024.10.003_bib33","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1177\/0310057X1604400113","article-title":"Discordance between ROTEM\u00ae clotting time and conventional tests during unfractionated heparin-based anticoagulation in intensive care patients on extracorporeal membrane oxygenation","volume":"44","author":"Prakash","year":"2016","journal-title":"Anaesth Intensive Care"},{"key":"10.1016\/j.avsg.2024.10.003_bib34","doi-asserted-by":"crossref","DOI":"10.1177\/15266028231199714","article-title":"Perprocedural heparinization in non-cardiac arterial procedures: the current practice in The Netherlands","author":"Roosendaal","year":"2023","journal-title":"J Endovasc Ther"},{"key":"10.1016\/j.avsg.2024.10.003_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ajcp\/aqy087","article-title":"Benefits and pitfalls of point-of-care coagulation testing for anticoagulation management: an ACLPS critical review","volume":"151","author":"Wool","year":"2019","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.avsg.2024.10.003_bib36","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.jvs.2010.10.124","article-title":"A randomized controlled trial of endovascular aneurysm repair versus open surgery for abdominal aortic aneurysms in low- to moderate-risk patients","volume":"53","author":"Becquemin","year":"2011","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.avsg.2024.10.003_bib37","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1056\/NEJMoa042002","article-title":"A randomized trial comparing conventional and endovascular repair of abdominal aortic aneurysms","volume":"351","author":"Prinssen","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.avsg.2024.10.003_bib38","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1002\/j.1552-4604.1988.tb03184.x","article-title":"The antithrombotic activity and pharmacokinetics of enoxaparine, a low molecular weight heparin, in humans given single subcutaneous doses of 20 to 80 mg","volume":"28","author":"Frydman","year":"1988","journal-title":"J Clin Pharmacol"}],"container-title":["Annals of Vascular Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890509624006496?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890509624006496?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T12:54:06Z","timestamp":1733748846000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0890509624006496"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":37,"alternative-id":["S0890509624006496"],"URL":"https:\/\/doi.org\/10.1016\/j.avsg.2024.10.003","relation":{},"ISSN":["0890-5096"],"issn-type":[{"value":"0890-5096","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ability of Activated Clotting Time Measurements to Monitor Unfractionated Heparin Activity During NonCardiac Arterial Procedures","name":"articletitle","label":"Article Title"},{"value":"Annals of Vascular Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.avsg.2024.10.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}